A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever (NCT06006559)
A Randomized, Participant- and Investigator-blinded, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever.
Who can join: Review the eligibility criteria below.
Location: Novartis Investigative Site — Manaus, Amazonas
Age range: 18 Years to 60 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (27 Sites)
Showing the first 25 of 27 sites.
- Novartis Investigative Site — Manaus, Amazonas
- Novartis Investigative Site — Brasília, Federal District
- Novartis Investigative Site — Rio de Janeiro, Rio de Janeiro
- Novartis Investigative Site — Porto Alegre, Rio Grande do Sul
- Novartis Investigative Site — São Caetano do Sul, São Paulo
- Novartis Investigative Site — São José do Rio Preto, São Paulo
- Novartis Investigative Site — Sorocaba, São Paulo
- Novartis Investigative Site — Barranquilla, Atlántico
- Novartis Investigative Site — Bucaramanga, Santander Department
- Novartis Investigative Site — Cali, Valle del Cauca Department
- Novartis Investigative Site — Belagavi, Karnataka
- Novartis Investigative Site — Mumbai, Maharashtra
- Novartis Investigative Site — Pune, Maharashtra
- Novartis Investigative Site — Jaipur, Rajasthan
- Novartis Investigative Site — Chennai, Tamil Nadu
- Novartis Investigative Site — Kuantan, Pahang
- Novartis Investigative Site — Ipoh, Perak
- Novartis Investigative Site — Seberang Jaya, Pulau Pinang
- Novartis Investigative Site — Miri, Sarawak
- Novartis Investigative Site — Kuala Selangor,
- Novartis Investigative Site — Oaxaca City,
- Novartis Investigative Site — Veracruz,
- Novartis Investigative Site — Singapore, Singapore
- Novartis Investigative Site — Singapore,
- Novartis Investigative Site — Haiphong,
📞 Contact the Study Coordinator
Phone: +41613241111
Email: novartis.email@novartis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Dengue
- Improving Disease Prevention Strategies by Integrating Socio-spatial Characterization of Human Mobility — Havana, La Habana
- Therapeutics for Moderate and Severe Dengue — Chittagong,
- Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative) — Baltimore, Maryland
- Dengue Vaccine Strategy in Children Aged 9 to 17 Years in the French Caribbean — Fort-de-France,
- Risk Factors for Hospitalization and Transfusion Criteria in Patients With Dengue Virus Infection — Piedras Negras, Coahuila
Explore by condition: All Dengue clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.